Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
The purpose of this research study is to test the safety of Niraparib and dostarlimab as a combination treatment and see what effects (good and bad) this combination treatment has on patients with recurrent or progressive cervix cancer.
Recurrent Cervix Cancer|Progressive Cervix Cancer
DRUG: Niraparib|DRUG: dostarlimab
Proportion of patients with response to treatment, The proportion of patients treated with Niraparib and dostarlimab who achieve CR or PR, evaluated using RECIST v1.1, 1 year
Number of patients who experience toxicity, To determine the nature and degree of toxicity in combination of Niraparib and dostarlimab, 2 years|Duration of patients with response, To estimate the duration of response of patients treated with combination of Niraparib and dostarlimab, up to 5 years|Progression free survival, To estimate the progression free survival of patients treated with combination of Niraparib and dostarlimab, up to 5 years|Overall survival, To estimate the overall survival of patients treated with combination of Niraparib and dostarlimab, up to 5 years
Patients will have tests and exams to see if they are eligible for the clinical trial. If found eligible, the patient will receive treatment with Niraparib daily and dostarlimab by vein every three weeks for 4 cycles then every six weeks.

Patients will receive the study treatment as long as there is evidence that the tumor is not growing or spreading and they are not having any unacceptable, bad side effects.

Patients will be monitored during treatment with tests and exams and after treatment completion for up to 5 years.